Revance Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Revance Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2012 to 2023.
  • Revance Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $92.8M, a 2743% increase year-over-year.
  • Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $137M, a 58.8% decline from 2022.
  • Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $332M, a 1010% increase from 2021.
  • Revance Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $29.9M, a 91% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $137M -$195M -58.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $332M +$302M +1010% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $29.9M -$302M -91% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $331M +$110M +49.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $222M +$220M +12339% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $1.78M -$194M -99.1% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $196M +$199M Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 -$2.64M -$145M -102% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 $143M -$86.5M -37.8% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-02
2014 $229M +$175M +324% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-28
2013 $54M +$40.4M +296% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-04
2012 $13.6M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.